Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[99mTc]Tc-EDDA-KL01127 is an experimental **PSMA-targeted technetium-99m radiopharmaceutical** being developed as a **SPECT imaging tracer** for **prostate cancer**. It is a Lys-urea-Aad pharmacophore-derived small-molecule ligand labeled with technetium-99m using an EDDA-based chelation system, designed to bind **prostate-specific membrane antigen** on prostate cancer cells and enable tumor visualization after intravenous administration. In the cited preclinical study, it showed successful imaging of LNCaP xenografts, predominantly renal clearance, and lower off-target uptake in spleen and salivary glands with improved tumor-to-background contrast relative to [99mTc]Tc-EDDA/HYNIC-iPSMA, supporting potential clinical translation as a PSMA SPECT diagnostic agent.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [99mTc]Tc-EDDA-KL01127.